Abstract
Primary cultures of neonatal rat cardiomyocytes were pretreated for 16 h with either nonselective (staurosporine, 100 nM) or selective (NPC15437, 20 microM) protein kinase C (PKC) inhibitors. These inhibitors did not affect the basal cytosolic free calcium, [Ca2+]i, level (106 +/- 12 nM) as determined by fura-2 fluorescence methodology. Both agents significantly enhanced the maximal [Ca2+]i responses to endothelin-1 (ET-1) and attenuated the peak [Ca2+]i responses to arginine vasopressin and angiotensin II. They did not alter the EC50 values of any of these agonists. Since depletion of [Ca2+]o led to only partial attenuation of the enhanced response to ET-1 in the treatment groups, it is likely that PKC inhibition results in an exaggerated intracellular mobilization of Ca2+ to ET-1. It is concluded that PKC modulates agonist(s)-evoked intracellular Ca2+ mobilization and that the nature of regulation is governed by the agonist.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Awazu M., Parker R. E., Harvie B. R., Ichikawa I., Kon V. Down-regulation of endothelin-1 receptors by protein kinase C in streptozotocin diabetic rats. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S500–S502. doi: 10.1097/00005344-199100177-00142. [DOI] [PubMed] [Google Scholar]
- Chardonnens D., Lang U., Rossier M. F., Capponi A. M., Vallotton M. B. Inhibitory and stimulatory effects of phorbol ester on vasopressin-induced cellular responses in cultured rat aortic smooth muscle cells. J Biol Chem. 1990 Jun 25;265(18):10451–10457. [PubMed] [Google Scholar]
- Iijima K., Lin L., Nasjletti A., Goligorsky M. S. Intracellular signaling pathway of endothelin-1. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S146–S149. doi: 10.1097/00005344-199100177-00040. [DOI] [PubMed] [Google Scholar]
- Kageyama M., Mori T., Yanagisawa T., Taira N. Is staurosporine a specific inhibitor of protein kinase C in intact porcine coronary arteries? J Pharmacol Exp Ther. 1991 Dec;259(3):1019–1026. [PubMed] [Google Scholar]
- Simonson M. S., Dunn M. J. Endothelins: a family of regulatory peptides. State-of-the-art lecture. Hypertension. 1991 Jun;17(6 Pt 2):856–863. doi: 10.1161/01.hyp.17.6.856. [DOI] [PubMed] [Google Scholar]
- Sugiura M., Inagami T., Hare G. M., Johns J. A. Endothelin action: Inhibition by a protein kinase C inhibitor and involvement of phosphoinositols. Biochem Biophys Res Commun. 1989 Jan 16;158(1):170–176. doi: 10.1016/s0006-291x(89)80193-7. [DOI] [PubMed] [Google Scholar]
- Sullivan J. P., Connor J. R., Shearer B. G., Burch R. M. 2,6-Diamino-N-([1-(1-oxotridecyl)-2-piperidinyl] methyl)hexanamide (NPC 15437): a novel inhibitor of protein kinase C interacting at the regulatory domain. Mol Pharmacol. 1992 Jan;41(1):38–44. [PubMed] [Google Scholar]
- Xu Y. J., Gopalakrishnan V. Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. Circ Res. 1991 Jul;69(1):239–245. doi: 10.1161/01.res.69.1.239. [DOI] [PubMed] [Google Scholar]